eligibility_summary
Adults (>=18) with advanced, unresectable/metastatic solid tumors lacking effective options, or multiple myeloma after >=3 prior lines incl PI, IMiD, anti-CD38. ECOG 0-2, measurable/evaluable disease, adequate organ and cardiac function, contraception required. Exclude significant cardiac/QT risks or QT-prolonging meds, active infection, hypersensitivity, lactation, serious comorbidities, recent therapy/radiation/surgery, >20 mg steroids, active liver disease, uncontrolled mood, autoimmune, or endocrine disorders.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: QXL138AM, a masked immunocytokine (biologic antibody–cytokine fusion) comprising an anti‑CD138 human IgG1 linked to human interferon‑α2a, administered IV every 2 weeks. Mechanism: the anti‑CD138 antibody targets syndecan‑1 (CD138) on malignant plasma cells and many epithelial tumors, concentrating IFN‑α at the tumor, where type I interferon signaling via IFNAR/JAK‑STAT induces antiproliferative/apoptotic effects, upregulates antigen presentation, and stimulates innate/adaptive immunity (dendritic cells, NK cells, CD8+ T cells). The IgG1 Fc may also engage Fcγ receptors to mediate ADCC/CDC against CD138+ cells. Cells/pathways targeted: CD138+ tumor cells (notably multiple myeloma and selected solid tumors) and the type I interferon (IFNAR–JAK/STAT) pathway in tumor and immune cells.